CA2790653C - Recombinant attenuated parvovirus - Google Patents

Recombinant attenuated parvovirus Download PDF

Info

Publication number
CA2790653C
CA2790653C CA2790653A CA2790653A CA2790653C CA 2790653 C CA2790653 C CA 2790653C CA 2790653 A CA2790653 A CA 2790653A CA 2790653 A CA2790653 A CA 2790653A CA 2790653 C CA2790653 C CA 2790653C
Authority
CA
Canada
Prior art keywords
parvovirus
capsid protein
dna
recombinant
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2790653A
Other languages
English (en)
French (fr)
Other versions
CA2790653A1 (en
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of CA2790653A1 publication Critical patent/CA2790653A1/en
Application granted granted Critical
Publication of CA2790653C publication Critical patent/CA2790653C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14361—Methods of inactivation or attenuation
    • C12N2750/14362—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2790653A 2010-03-05 2011-03-03 Recombinant attenuated parvovirus Active CA2790653C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31103210P 2010-03-05 2010-03-05
US61/311,032 2010-03-05
EP10155646 2010-03-05
EP10155646.2 2010-03-05
PCT/EP2011/053164 WO2011107534A1 (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Publications (2)

Publication Number Publication Date
CA2790653A1 CA2790653A1 (en) 2011-09-09
CA2790653C true CA2790653C (en) 2019-02-19

Family

ID=42562704

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2790653A Active CA2790653C (en) 2010-03-05 2011-03-03 Recombinant attenuated parvovirus

Country Status (10)

Country Link
US (1) US9234182B2 (enExample)
EP (1) EP2542260B1 (enExample)
JP (3) JP6200155B2 (enExample)
CN (1) CN102791288B (enExample)
AU (1) AU2011222910B2 (enExample)
CA (1) CA2790653C (enExample)
DK (1) DK2542260T3 (enExample)
ES (1) ES2566033T3 (enExample)
RU (1) RU2527157C2 (enExample)
WO (1) WO2011107534A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107534A1 (en) * 2010-03-05 2011-09-09 Intervet International B.V. Recombinant attenuated parvovirus
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
US20140234354A1 (en) * 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
CN105263953B (zh) * 2014-01-15 2020-01-07 勃林格殷格翰动物保健美国有限公司 猪细小病毒5a、使用方法及疫苗
US10398773B2 (en) 2014-04-17 2019-09-03 Intervet Inc. Porcine parvovirus
UA130511C2 (uk) 2016-11-03 2026-03-11 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання
EP4570264A3 (en) 2016-11-03 2026-01-21 Boehringer Ingelheim Vetmedica GmbH Vaccine against porcine parvovirus
MX2023005182A (es) 2020-11-04 2023-05-15 Intervet Int Bv Parvovirus canino.
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8502399D0 (en) * 1985-01-31 1985-03-06 Akzo Nv Canine parvovirus vaccines
EP1135468B1 (en) * 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
EP1912665B1 (en) * 2005-07-28 2011-01-26 Pfizer Products Inc. Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto.
SG182206A1 (en) * 2007-06-14 2012-07-30 Univ Oklahoma State Vaccines containing canine parvovirus genetic variants
WO2011107534A1 (en) * 2010-03-05 2011-09-09 Intervet International B.V. Recombinant attenuated parvovirus

Also Published As

Publication number Publication date
JP2018134088A (ja) 2018-08-30
US20120328652A1 (en) 2012-12-27
US9234182B2 (en) 2016-01-12
DK2542260T3 (en) 2016-06-06
RU2527157C2 (ru) 2014-08-27
JP2013520977A (ja) 2013-06-10
WO2011107534A1 (en) 2011-09-09
CN102791288B (zh) 2015-02-18
JP2016047053A (ja) 2016-04-07
BR112012021650A2 (pt) 2017-02-21
JP6200155B2 (ja) 2017-09-20
EP2542260B1 (en) 2016-03-02
CN102791288A (zh) 2012-11-21
AU2011222910A1 (en) 2012-09-27
AU2011222910B2 (en) 2014-09-18
JP6346143B2 (ja) 2018-06-20
RU2012142309A (ru) 2014-04-10
ES2566033T3 (es) 2016-04-08
EP2542260A1 (en) 2013-01-09
CA2790653A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
AU2011222910B2 (en) Recombinant attenuated parvovirus
JP7661552B2 (ja) ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法
EP2593136B1 (en) Live attenuated parvovirus
AU2009303845A1 (en) Torque teno virus (TTV) isolates and compositions
CN116390753A (zh) 犬细小病毒
JP2019516745A (ja) Ｈｅｖワクチン
Chang et al. Enhanced production of Canine parvovirus VP2 protein using improved Baculovirus expression system and its immunogenicity
BR112012021650B1 (pt) Parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção do referido parvovírus recombinante e seu uso
ES2783898T3 (es) Parvovirus atenuado vivo
WO2024115785A1 (en) Vaccine
AU2014262215A1 (en) Porcine Torque teno virus vaccines and diagnosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251209